A practical reference on stability testing: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-03-09 and is reviewed periodically as new material appears.
Testing hydrolysate powders typically begins with proximate analysis for moisture, ash, fat, and total nitrogen. Protein content is calculated from nitrogen using a conversion factor, most often Kjeldahl or Dumas combustion. Peptide size distribution is assessed by size-exclusion chromatography, reversed-phase HPLC, or mass spectrometry. Sodium dodecyl sulfate polyacrylamide gel electrophoresis can show residual intact protein bands. Free amino groups may be quantified by colorimetric assays to estimate cleavage extent, though different methods and laboratories are not always directly comparable.
Dry hydrolysate powders are generally stable when kept cool, dry, and sealed, while moisture uptake can cause caking, Maillard browning, and loss of solubility. Higher temperatures accelerate these changes and may alter flavor. Recommended storage conditions often fall between 15 and 25 degrees Celsius with relative humidity below 60 percent. Once reconstituted, liquid hydrolysate solutions support microbial growth and may develop bitterness or haze over time. Packaging in moisture-barrier containers with desiccants helps maintain quality during transport and warehouse storage.
Quality control for hydrolysate ingredients focuses on identity, purity, and consistency, with specifications that may include total protein, hydrolysis level, molecular weight distribution, microbiological limits, heavy metals, and allergen labeling. In some jurisdictions, partially and extensively hydrolyzed formulas are regulated as foods for special dietary uses or as infant formula ingredients. Regulatory status varies by country and intended use. Documentation such as certificates of analysis, safety data sheets, and method validation records supports traceability. Open questions remain about standardizing hydrolysis measurements across suppliers and laboratories.
Quality control for whey protein hydrolysate begins with specification of protein, moisture, ash, fat, lactose, and degree of hydrolysis, while molecular weight distribution is measured by size-exclusion chromatography or electrophoresis. Free amino acid content can be quantified by amino acid analysis. Microbial limits, heavy metals, and residual enzyme activity are also monitored. Because hydrolysis conditions influence batch consistency, manufacturers validate processes and test each lot against release criteria. Sampling plans and reference standards help compare results across laboratories.
Storage stability depends on moisture, temperature, oxygen, and packaging, and hydrolysates are hygroscopic and can cake when exposed to humid air. Maillard reactions between peptides and residual lactose can cause browning and flavor changes during warm storage, while lipid oxidation may develop if residual fat is present. Cool, dry conditions and sealed containers slow these reactions. Shelf-life studies typically monitor moisture, color, solubility, molecular weight profile, and microbial counts over time. Accelerated tests estimate stability, but real-time data remain the reference for shelf-life assignment.
Regulatory status differs by country and intended use. In many jurisdictions, whey protein hydrolysate is regulated as a food ingredient, while specific infant formula or medical food uses may require additional review. Labeling rules govern protein content claims, allergen statements, and terms such as partially hydrolyzed or extensively hydrolyzed. Analytical methods for degree of hydrolysis are not fully standardized, so values can depend on the assay. This variability makes direct comparison between products difficult unless the method and reference material are stated.
| Property | Value | Notes |
|---|---|---|
| Moisture content | ≤5% typical | Higher moisture promotes caking and browning |
| pH (5% solution) | 6.0–7.5 typical | Varies with hydrolysis and neutralization |
| Ash content | 1–8% | Depends on demineralization and neutralization salts |
| Microbiological limit | Total aerobic count <10^4 CFU/g typical | Specifications vary by grade and market |
| Shelf life | 12–24 months unopened | Cool, dry storage extends stability |
Storage stability depends on moisture, temperature, oxygen, and packaging. Dry hydrolysate powders are typically stable for months to years when kept cool and sealed, but they can absorb water and cake if exposed to humid air. Higher temperatures accelerate Maillard reactions between peptides and residual sugars, leading to browning and flavor changes. Lipid oxidation can occur if residual fat is present, producing off-odors. Once a powder is reconstituted, microbial growth becomes a concern, so liquid forms require refrigeration or other preservation steps.
Quality control for hydrolysates often includes allergen and contaminant checks. Because whey is a milk-derived ingredient, milk protein residues may remain, and the extent to which hydrolysis reduces allergenic potential is product-specific and not fully predictable. Tests may screen for heavy metals, melamine, pesticides, and microbial indicators. Enzyme residues and processing aids are also monitored when regulations require it. Batch-to-batch consistency is assessed through peptide mapping or functional tests, since small process changes can alter taste, solubility, or nutritional performance.
Commercial production begins with whey protein concentrate or isolate dissolved in water. A protease is added under controlled pH and temperature, and the reaction is stopped by heat or pH adjustment once a target degree of hydrolysis is reached. Membrane filtration, often ultrafiltration or diafiltration, removes enzymes and small solutes while retaining peptides. The liquid is then concentrated and spray-dried into a powder. Each step influences peptide length, mineral content, and flavor.
Quality control focuses on degree of hydrolysis, molecular weight distribution, protein content, moisture, ash, and microbial limits. Degree of hydrolysis is commonly calculated from the number of cleaved peptide bonds relative to total peptide bonds. Size-exclusion chromatography and mass spectrometry can describe peptide size ranges, while amino acid analysis quantifies composition. Standard methods from dairy science organizations are often used, though no single method captures every functional property. Results are therefore reported alongside processing conditions.
Hydrolysates are generally stable as dry powders but can absorb moisture and undergo browning during warm storage. The bitter taste of some hydrolysates arises from hydrophobic peptides exposed by cleavage, and it varies with enzyme choice and degree of hydrolysis. Reduced allergenicity is sometimes claimed, but residual IgE-binding peptides may remain, especially in partial hydrolysates. Regulatory frameworks treat extensively hydrolyzed and partially hydrolyzed products differently, and labeling rules vary by country. More research is needed on how specific peptide profiles relate to clinical outcomes.
Miguel Angel Ondetti (May 14, 1930 – August 23, 2004) was an Argentine-born American chemist who first synthesized captopril, the first ACE inhibitor that was used to treat heart disease. With his co-worker, David Cushman, he won the 1999 Lasker Award, with David Cushman, for: "developing an innovative approach to drug design based on protein structure and using it to create the ACE inhibitors, powerful oral agents for the treatment of high blood pressure, heart failure, and diabetic kidney disease". Ondetti was born and raised in Buenos Aires and received a PhD in chemistry from the University of Buenos Aires, in his hometown, in 1957. In 1960 he moved to The Squibb Institute for Medical Research in New Jersey where he researched and developed Captopril in 1975.
== Pharmacology == Dihydrocodeine exerts its analgesic action through affinity to predominantly μ-opioid receptor and to lesser extent to κ-opioid receptor and δ-opioid receptor. A 1956 source states that 30 mg of subcutaneous dihydrocodeine is equianalgesic to 10 mg of morphine. Another source states that dihydrocodeine is twice as strong as codeine and the metabolite dihydromorphine is likewise twice as strong as morphine. Dihydrocodeine (DHC) is O-demethylated into dihydromorphine (DHM) by CYP2D6 and N-demethylated into nordihydrocodeine (NDHC) by CYP3A4, summarily yielding nordihydromorphine (NDHM). Dihydrocodeine and its metabolites form 3- and 6-glucuronides. Due to the multidirectional metabolism, as opposed to tramadol and codeine, CYP2D6 activity probably does not influence DHC analgesia. The analgesia is likely achieved by the action of DHC itself, as well as DHC-6-G. DHC appears not to differ between poor and extensive metabolizers in terms of its pain threshold and pupillary reaction effect in spite of major variation in DHM blood levels. DHC-6-G is half as potent as DHC. DHM and DHM-6-G display the highest affinity to μ-opioid receptors, being 70 times as potent as DHC, whereas other metabolites display lesser affinity. DHM-6-G has similar potency as DHM, while DHM-3-G is considerably weaker. Action on δ-opioid receptor is 5-50 weaker compared to μ with the exception of DHC-6-G being twice as strong as DHC. 6-glucuronides possess lesser affinity towards κ-opioid receptors, albeit the affinity of DHC is comparable to codeine, DHM and morphine.
Following the first presidential debate of the general election, in which Obama's performance was considered surprisingly lackluster, his lead over Romney collapsed, putting pressure on Biden to stop the bleeding with a strong showing against the Republican vice-presidential nominee, Paul Ryan. Some political analysts considered Biden's performance in the October 11 vice-presidential debate one of the best of his career and a key factor in Obama's rebound in the polls and eventual victory. The debate also became memorable for the popularization of Biden's use of the phrase "a bunch of malarkey" in response to an attack by Ryan on the administration's response to the attacks on the U.S. embassy in Benghazi in September. Biden reused the phrase during his 2020 presidential campaign. On November 6, Obama and Biden were reelected.
Sources: en.wikipedia.org
=== Powder feeding in continuous manufacturing === In continuous manufacturing, input raw materials and energy are fed into the system at a constant rate, and at the same time, a constant extraction of output products is achieved. The process's performance is heavily dependent on the stability of the material flowrate. For powder-based continuous processes, it is critical to feed powders consistently and accurately into subsequent unit operations of the process line, as feeding is typically the first unit operation. Feeders have been designed to achieve performance reliability, feed rate accuracy, and minimal disturbances. Accurate and consistent delivery of materials by well-designed feeders ensures overall process stability. Loss-in-weight (LIW) feeders are selected for pharmaceutical manufacturing. Loss-in-weight (LIW) feeders control material dispensing by weight at a precise rate and are often selected to minimize the flowrate variability that is caused by change of fill level and material bulk density. Importantly, feeding performance is strongly dependent on powder flow properties.
Aged mouse tissues exhibit globally increased malonylation, potentially due to elevated expression of acetyl-CoA carboxylase and reduced activity of the deacylase SIRT5, which depends on declining NAD+ levels. These findings suggest a role for histone malonylation in the epigenetic regulation of aging processes. In type 2 diabetes, lysine malonylation is significantly elevated in liver tissue, as shown in obese mouse models such as db/db and ob/ob mice. Many of the affected proteins are involved in glucose and lipid metabolism, and malonylation of glycolytic enzymes has been shown to suppress their activity, leading to reduced glycolytic flux. Six of the ten glycolytic enzymes are malonylated at sites regulated by the demalonylase SIRT5, which counteracts this inhibition and may serve as a therapeutic target, along with other yet unidentified enzymes that regulate malonylation. In osteoarthritis, SIRT5 expression decreases in cartilage during aging while lysine malonylation increases. In mice, the combination of Sirt5 deficiency and high-fat diet–induced obesity exacerbates joint degeneration, accompanied by widespread hypermalonylation of glycolytic enzymes and impaired chondrocyte metabolism. A rare missense mutation in human SIRT5 (F101L) found in familial osteoarthritis further confirms a direct link between hypermalonylation and osteoarthritis. In resting macrophages, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) binds to inflammatory mRNAs such as TNFα and suppresses their translation.
According to legends, the history of theriac begins with the king Mithridates VI of Pontus who experimented with poisons and antidotes on his prisoners. His numerous toxicity experiments eventually led him to declare that he had discovered an antidote for every venomous reptile and poisonous substance. He mixed all the effective antidotes into a single one, mithridatium or mithridate. Mithridate contained opium, myrrh, saffron, ginger, cinnamon and castor, along with some forty other ingredients. When the Romans defeated him, his medical notes fell into their hands and Roman medici began to use them. Emperor Nero's physician Andromachus improved upon mithridatum by bringing the total number of ingredients to sixty-four, including viper's flesh, a mashed decoction of which, first roasted then well aged, proved the most constant ingredient. Lise Manniche, however, links the origins of theriac to the ancient Egyptian kyphi recipe, which was also used medicinally. Greek physician Galen devoted a whole book, Theriaké, to theriac, documenting many notable theriacs such as Philonium. One of his patients, Roman emperor Marcus Aurelius, took it on a regular basis. In 667, ambassadors from Rûm presented the Emperor Gaozong of the Tang dynasty in China with a theriac. The Chinese observed that it contained the gall of swine, was dark red in colour and the foreigners seemed to respect it greatly. The Tang pharmacologist Su Kung noted that it had proved its usefulness against "the hundred ailments".
=== Legal status === On 13 October 2022, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Locametz, intended for the diagnosis of prostate cancer. The applicant for this medicinal product is Novartis Europharm Limited. Locametz was approved for medical use in the European Union in December 2022.
Sources: en.wikipedia.org
When both types of loxoscelism do result, systemic effects may occur before necrosis, as the venom spreads throughout the body in minutes. Children, the elderly, and the debilitatingly ill may be more susceptible to systemic loxoscelism. The systemic symptoms most commonly experienced include nausea, vomiting, fever, rashes, and muscle and joint pain. Rarely, such bites can result in hemolysis, low platelet levels, blood clots throughout the body, organ damage, and even death. Most fatalities are in children under the age of seven or those with a weak immune system. While the majority of brown recluse spider bites do not result in any symptoms, cutaneous symptoms occur more frequently than systemic symptoms. In such instances, the bite forms a necrotizing ulcer as the result of soft tissue destruction and may take months to heal, leaving deep scars. These bites usually become painful and itchy within 2–8 hours. Pain and other local effects worsen 12–36 hours after the bite, and the necrosis develops over the next few days. Over time, the wound may grow to as large as 25 cm (10 inches). The damaged tissue becomes gangrenous and eventually sloughs away. L. reclusa can produce slightly more than 0.1 μL of venom, though the average yield is less.
=== Translational repression === The translation initiation factor eIF4E is tightly regulated by the fragile X mental retardation protein (FMRP), which controls the translation of specific mRNAs at synapses. FMRP interacts with CYFIP1, which directly binds eIF4E at a domain structurally analogous to those found in canonical 4E-binding proteins such as EIF4EBP1, EIF4EBP2, and EIF4EBP3. This interaction competitively inhibits eIF4G binding, thereby blocking assembly of the eukaryotic translation initiation complex and repressing translation. The FMRP–CYFIP1–eIF4E complex is further stabilized by dendritically localized, non-coding RNAs such as BC1, which enhance FMRP-CYFIP1 interactions and mediate recruitment to specific target mRNAs. This repressive complex is responsive to neuronal stimulation. Synaptic activity promotes the dissociation of CYFIP1 from eIF4E, thereby allowing eIF4G to bind and initiate translation. This mechanism enables dynamic, activity-dependent regulation of protein synthesis at the synapse, contributing to processes such as synaptic plasticity and learning. Since eIF4E is an initiation factor that is relatively low in abundance, eIF4E can be controlled at multiple levels. Regulation of eIF4E may be achieved at the levels of transcription, RNA stability phosphorylation, subcellular localization and partner proteins.
== Evolution == The oldest trace fossils on bones characteristic of Osedax are from a plesiosaur humerus from the Cambridge Greensand, England, likely reworked from late Albian (c. 100 million years old) sediments and a rib and costal plate from a sea turtle found in Cenomanian (100–93 million years ago) aged sediments of the Chalk Group, England. Further material is known from the Campanian and Maastrichtian. Following the extinction of almost all large marine reptiles at the end of the Cretaceous, Osedax likely persisted on the bones of sea turtles, marine birds, and fish.
Sources: en.wikipedia.org
Keep the powder sealed in a cool, dry place away from direct sunlight and strong odors. Typical targets are 15 to 25 degrees Celsius and low relative humidity. After opening, use within the manufacturer's recommended period.
Size-exclusion chromatography and mass spectrometry provide molecular weight or mass information. Electrophoresis can reveal intact protein bands and larger fragments. No single method captures the complete peptide profile.
Not always, because assays and calculation methods differ. Values may reflect free amino groups, pH change, or nitrogen solubility. Comparisons require method details and reference standards.
Methods include trinitrobenzenesulfonic acid assay, o-phthaldialdehyde assay, formol titration, and nitrogen solubility. Values depend on calibration and assay conditions. Results should be interpreted with the stated method.